Skip to main content

Table 2 The changes of serologic markers at three clinical situations in HPD, SD, and PR/CR groups (n = 155)a

From: The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy

Serologic marker HPD SD PR/CR P value
(n = 26) (n = 79) (n = 50)
At the beginning of prior treatment
 NLR <  5 vs. ≥ 5 17:9 58:21 39:11 0.341
 PLR <  150 vs. ≥ 150 8:18 33:46 16:34 0.835
 CAR <  0.5 vs. ≥ 0.5 12:14 63:16 40:10 0.004
 LDH <  400 vs. ≥ 400 9:17 30:49 17:33 0.706
At the beginning of immunotherapy
 NLR <  5 vs. ≥ 5 17:9 65:14 39:11 0.203
 PLR <  150 vs. ≥ 150 8:18 33:46 22:28 0.265
 CAR <  0.5 vs. ≥ 0.5 10:16 57:22 32:18 0.026
 LDH <  400 vs. ≥ 400 10:16 26:53 18:32 0.581
At 1st tumor response assessment (6–8 weeks after initiation of ICBs)
 NLR <  5 vs. ≥ 5 8:18 71:8 45:5 0.000
 PLR <  150 vs. ≥ 150 7:19 42:37 29:21 0.004
 CAR < 0.5 vs. ≥ 0.5 9:17 56:23 32:18 0.001
 LDH <  400 vs. ≥ 400 4:22 24:55 19:31 0.043
  1. a Non-evaluable group and Non-HPD PD group were excluded
  2. CAR C-reactive protein-albumin ratio, ICB immune checkpoint blockades, LDH lactate dehydrogenase, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio